AIMOVIG (erenumab) has been registered in Australia as the first and only treatment targeting the calcitonin gene-related peptide (CGRP) receptor for the prophylaxis of migraine in adults, providing a new and specifically targeted preventive approach.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Aug 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Aug 18
